다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
The Korean journal of internal medicine : KJIM, v.20 no.2, 2005년, pp.135 - 140
Shin, Sang Joon (Division of Oncology-Hematology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.) , Chun, Sung Ho (Division of Oncology-Hematology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.) , Kim, Kyeong Ok (Division of Oncology-Hematology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.) , Kim, Min Kyoung (Division of Oncology-Hematology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.) , Lee, Kyung Hee (Division of Oncology-Hematology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.) , Hyun, Myung Soo (Division of Oncology-Hematology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.) , Bae, Sung Hwa (Department of Internal Medicine, Daegu Catholic University Hospital, Daegu, Korea.) , Ryoo, Hun Mo (Department of Internal Medicine, Daegu Catholic University Hospital, Daegu, Korea.) , Do, Young Rok (Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.) , Kwon, Ki Young (Dep) , Song, Hong Suk
AI-Helper
BackgroundAlthough many treatments for advanced gastric cancer have been developed, only poor treatment results have generally been obtained. We performed a prospective study on the combination chemotherapy of paclitaxel and cisplatin (PC). The primary objectives of the study were elucidating the di...
1 Wong JE Ito Y Correa P Peeters KC van de Velde CJ Sasako M Macdonald J Therapeutic strategies in gastric cancer J Clin Oncol 2003 21 267s 269s 14645406
2 Macdonald JS Smalley SR Benedetti J Hundahl SA Estes NC Stemmermann GN Haller DG Ajani JA Gunderson LL Jessup JM Martenson JA Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 2001 345 725 730 11547741
3 Parker SL Tong T Bolden S Wingo PA Cancer statistics, 1996 CA Cancer J Clin 1996 46 5 27 8548526
4 Pyrhonen S Kuitunen T Nyandoto P Kouri M Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 1995 71 587 591 7533517
5 MacDonald JS Schein PS Woolley PV Smythe T Ueno W Hoth D Smith F Boiron M Gisselbrecht C Brunet R Lagarde C 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer Ann Intern Med 1980 93 533 536 7436184
6 Cullinan SA Moertel CG Fleming TR Rubin JR Krook JE Everson LK Windschitl HE Twito DI Marschke RF Foley JF A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin JAMA 1985 253 2061 2067 2579257
7 Chang YF Li LL Wu CW Liu TY Liu WY Peng FK Chi CW Paclitaxel-induced apoptosis in human gastric carcinoma cell lines Cancer 1996 77 14 18 8630921
8 Matsuoka H Yano K Saito T Seo Y Tomoda H Cytotoxicity of paclitaxel in comparison with other anticancer agents against neoplastic cells obtained from clinical gastrointestinal carcinoma tissue Anticancer Res 1995 15 2001 2006 8572592
9 Cascinu S Graziano F Cardarelli N Marcellini M Giordani P Menichetti ET Catalano G Phase II study of paclitaxel in pretreated advanced gastric cancer Anticancer Drugs 1998 9 307 310 9635920
10 Thigpen JT Blessing JA Beecham J Homesley H Yordan E Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas J Clin Oncol 1991 9 1962 1966 1941054
11 Vanhoefer U Harstrick A Wilke H Schleucher N Walles H Schroder J Seeber S Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro Eur J Cancer 1995 31A 92 97 7695986
12 Ilson DH Ajani J Bhalla K Forastiere A Huang Y Patel P Martin L Donegan J Pazdur R Reed C Kelsen DP Phase II trial of paclitaxel, fluorouracil, cisplatin in patients with advanced carcinoma of the esophagus J Clin Oncol 1998 16 1826 1834 9586897
13 Khuri FR Shin DM Glisson BS Lippman SM Hong WK Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions Semin Oncol 2000 27 4 Suppl 8 25 33 10952435
14 Gatzemeier U von Pawel J Gottfried M ten Velde GP Mattson K DeMarinis F Harper P Salvati F Robinet G Lucenti A Bogaerts J Gallant G Phase III comparative study of high dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer J Clin Oncol 2000 18 3390 3399 11013280
15 Pfisterer J Optimierung der primären Chemotherapie des fortgeschrittenen Ovarialkarzinoms Onkologie 2000 23 31 43
16 Kornek GV Raderer M Schull B Fiebiger W Gedlicka C Lenauer A Depisch D Schneeweiss B Lang F Scheithauer W Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer Br J Cancer 2002 86 1858 1863 12085176
17 Kollmannsberger C Quietzsch D Haag C Lingenfelser T Schroeder M Hartmann JT Baronius W Hempel V Clemens M Kanz L Bokemeyer C A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer Br J Cancer 2000 83 458 462 10945491
18 Honecker F Kollmannsberger C Quietzsch D Haag C Schroeder M Spott C Hartmann JT Baronius W Hempel V Kanz L Bokemeyer C Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer Anticancer Drugs 2002 13 497 503 12045461
19 Park SR Oh DY Kim DW Kim TY Heo DS Bang YJ Kim NK Kang WK Kim HT Im SA Suh JH Kim HK Kim HK A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer Oncol Rep 2004 12 1059 1064 15492793
20 Simon R How large should a phase II trial of a new drug be? Cancer Treat Rep 1987 71 1079 1085 3315196
21 Kaplan EL Meier P Non-parametric estimation from incomplete observations J Am Stat Assoc 1958 53 458 481
22 Ajani JA Fairweather J Dumas P Patt YZ Pazdur R Mansfield PF A phase II study of Taxol in patients with advanced untreated gastric carcinoma [Abstract] Proc Annu Meet Am Soc Clin Oncol 1997 16 A933
23 Ohtsu A Boku N Tamura F Muro K Shimada Y Saigenji K Akazawa S Kitajima M Kanamaru R Taguchi T An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer Am J Clin Oncol 1998 21 416 419 9708646
24 Wils J The treatment of advanced gastric cancer Semin Oncol 1996 23 397 406 8658224
25 Roth AD Maibach R Martinelli G Fazio N Aapro MS Pagani O Morant R Borner MM Herrmann R Honegger H Cavalli F Alberto P Castiglione M Goldhirsch A Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma Ann Oncol 2000 11 301 306 10811496
26 Ridwelski K Gebauer T Fahlke J Kroning H Kettner E Meyer F Eichelmann K Lippert H Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer Ann Oncol 2001 12 47 51 11249048
27 Ajani JA van Cutsem E Moiseyenko V Tjulandin S Fodor M Majlis A Boni C Zuber E Blattmann A Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V325) Proc Am Soc Clin Oncol 2003 22 249
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.